\
&
Contact us
Published on | 11 months ago
ProgrammesThe European Commission has launched an open call for applications for two new initiatives under the EU Defence Innovation Scheme (EUDIS): the EUDIS Business Accelerator and EUDIS Matchmaking.
EUDIS Business Accelerator
An intensive 8-month acceleration programme designed for European startups and scale-ups. Participants will benefit from:
Apply by April 27 → More information & application
EUDIS Matchmaking
A tailored matchmaking initiative bringing together the whole European defence innovation ecosystem, including innovators, investors, end-users, and corporates. The programme includes:
Continuous open call – early applications encouraged → More information & application
If you’d like to find out more, join the Info Webinars:
EUDIS Matchmaking Webinar – April 8 → Register here
EUDIS Business Accelerator Webinar – April 10 → Register here
We invite you to seize this opportunity to accelerate your growth, access funding, and integrate into the European defence innovation ecosystem.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.